There have been multiple threads recently on Pre-PMF and early stage MF. My very limited understanding is that Pre-MF can be hard to distinguish, even via BMB, from ET.
My original BMB was plain ET, a second BMB 15 months later produced one dx of ET and another of PV/MPN-U (I had two cores taken, sent to different labs). MPN-U (the U stands for Unclassified) appears to be a euphemism for Pre-PMF (see the link below re should Pre-MF be a separate classification, that c. 15-25% of MPN’s are Pre-PMF).
bloodjournal.org/content/12...
Pre-PMF sounds scary but this article states prognosis similar to PV. Imo the important part is not exactly where we are on the sliding scale from ET to MF but how fast we are travelling.
So what should we be focussing on?
First aspect to consider is what is the best drug option. I’ve gone for Pegasys (Interferon). Bit of a leap of faith since expert opinion split re benefits versus risks but it does appear to reduce Allele Burden and improve fibrosis in a subset of patients. It’s effectively three rolls of the dice, 1) can I tolerate the side effects, 2) will I be one of the lucky ones who gets molecular response and 3) how meaningful is this molecular response long term. I’ve had no side effects on 60 mcg weekly (some are taking 180mcg) and I’ve had good early haematological response. Will get Allele Burden checked in two months.
Can I suggest that anyone thinking about Pegasys watches this recent video panel discussion between two Interferon bulls. And then google searches Interferon v HU etc.
Re starting Ruxo, my understanding is that one of the problems is that, for some, it only works for c. 4 years? Hence I wouldn’t want to start until I really need it. Also it extends life by improving symptoms, as far as I’m aware it doesn’t slow progression in the way that the bulls claim that Interferon does.
It appears there are effectively 5 stages of progression? Pre-PMF, early stage PMF or secondary MF, Intermediate 1, Intermediate 2 and then final stage. Normally Hems will advise SCT at Intermediate 2 stage but if the patient has developed high risk mutations such as ASXL1, they will likely advice transplant at Intermediate 1. Hence, if we are open to SCT option, we want to know if/when we reach Intermediate 1 so that can request Myeloid Panel test to identify any adverse mutations.
The questions I’m going to ask next time are: Will changing blood counts/symptoms give advance warning signs of progression to Intermediate 1? Or is it possible to progress with stable blood counts and no new symptoms? And if we are controlling our counts with HU/Peg, does this ‘muddy the waters’?
Best Paul